Michael Zile to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Michael Zile has written about Diabetes Mellitus, Type 2.
Connection Strength
0.673
-
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
Score: 0.315
-
Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
Score: 0.086
-
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 08; 21(8):974-984.
Score: 0.086
-
The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019 01; 21(1):40-49.
Score: 0.082
-
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21; 135(8):724-735.
Score: 0.072
-
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 05; 5(5):333-340.
Score: 0.018
-
Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest. 2012 Nov; 122(11):3919-30.
Score: 0.013